UNSPSC 51282701: Teicoplanin

This classification denotes an antibiotic with the molecular formula C58H42CL2N7O18(R1)(R2)(R3), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U3D3YY81M, more generally known as teicoplanin. European Medicines Agency schedules teicoplanin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04714MIG. The term TEICOPLANIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.

TEICOPLANIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teicoplanin under HS 29419000 and SITC 54139. As of Q4 2014, TEICOPLANIN remains the US FDA Preferred Term for this commodity. Teicoplanin bears US NLM identifiers UMLS ID C0145106 and NCI Concept Code C1412.

UNSPSC 51282701 Teicoplanin is a Commodity code for a specific antibiotic pharmaceutical product, yet the recent state and local opportunities tagged under it do not reflect teicoplanin procurement. Instead, the tagged solicitations cover naloxone (an opioid antagonist) and other pharmaceutical products unrelated to the code's nominal scope. State and local governments purchasing under this code would typically seek teicoplanin supplies for hospital pharmacy systems, emergency departments, or public health emergency stockpiles, but no active teicoplanin solicitations appear in the recent opportunity record. The mismatch between the code's product scope and the actual opportunities posted suggests either inconsistent tagging by issuing bodies or limited recent state and local demand for teicoplanin specifically.

The recent opportunities show pharmaceutical procurement activity across state departments and counties, with the Illinois Department of Public Health awarding a piggyback contract to Chartwell Rx LLC for antibiotic tablets (doxycycline and ciprofloxacin) through the MMCAP Infuse consortium in August 2026, and Seminole County, Florida issuing an IFB in June 2026 for naloxone and drug deactivation systems with quarterly deliveries. Neither opportunity involves teicoplanin. Without representative recent teicoplanin solicitations, the code shows minimal actionable activity for vendors focused on this specific antibiotic supply line.